To the Editor We read with interest the Review by Cappuyns and colleagues¹ comparing the clinical benefit and safety profile of the recommended first-line and second-line drug regimens for advanced hepatocellular carcinoma (HCC). However, we have identified errors in the article, including an incorrect reference to guidelines limiting the STRIDE (single tremelimumab regular interval durvalumab) regimen to patients ineligible to receive bevacizumab rather than as a preferred first-line regimen. The American Association for the Study of Liver Diseases guidance document cited in the article (and published May 2023) indicates: 鈥淪ystemic therapies with atezolizumab plus bevacizumab or durvalumab plus tremelimumab are considered as preferred first-line therapy options.鈥� In addition, the authors¹ self-tabulated a European Society for Medical Oncology鈥揗agnitude of Clinical Benefit Scale (ESMO-MCBS) score of 3 for STRIDE, which in actuality was assessed as a 5 (November 2022) and reflected as such in the ESMO-MCBS scorecard.² It follows that these errors should be addressed to more accurately inform the medical community of the current state of systemic therapies available to help patients with HCC.